Cargando…
An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
The U.S. Food and Drug Administration (FDA) created the GenomeTrakr Whole Genome Sequencing (WGS) Network in 2013, as a tool to improve food safety. This study presents an analysis of Whole Genome source tracking implementation on potential food contamination and related illnesses through theoretica...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494326/ https://www.ncbi.nlm.nih.gov/pubmed/34614029 http://dx.doi.org/10.1371/journal.pone.0258262 |
_version_ | 1784579287746084864 |
---|---|
author | Brown, Brad Allard, Marc Bazaco, Michael C. Blankenship, Joseph Minor, Travis |
author_facet | Brown, Brad Allard, Marc Bazaco, Michael C. Blankenship, Joseph Minor, Travis |
author_sort | Brown, Brad |
collection | PubMed |
description | The U.S. Food and Drug Administration (FDA) created the GenomeTrakr Whole Genome Sequencing (WGS) Network in 2013, as a tool to improve food safety. This study presents an analysis of Whole Genome source tracking implementation on potential food contamination and related illnesses through theoretical, empirical, and cost benefit analyses. We conduct empirical tests using data from FDA regulated food commodity outbreaks garnering FDA response from 1999 through 2019 and examine the effect of the National Center for Biotechnology Information (NCBI) Pathogen detection program of source tracking WGS isolates collected in the U.S. on outbreak illnesses for three pilot pathogens (E. coli, Listeria, and Salmonella). Empirical results are consistent with the theoretical model and suggest that each additional 1,000 WGS isolates added to the public NCBI database is associated with a reduction of approximately 6 illnesses per WGS pathogen, per year. Empirical results are connected to existing literature for a Monte Carlo analysis to estimate benefits and costs. By 2019, annual health benefits are estimated at nearly $500 million, compared to an approximately $22 million investment by public health agencies. Even under conservative assumptions, the program likely broke even in its second year of implementation and could produce increasing public health benefits as the GenomeTrakr network matures. |
format | Online Article Text |
id | pubmed-8494326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84943262021-10-07 An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S. Brown, Brad Allard, Marc Bazaco, Michael C. Blankenship, Joseph Minor, Travis PLoS One Research Article The U.S. Food and Drug Administration (FDA) created the GenomeTrakr Whole Genome Sequencing (WGS) Network in 2013, as a tool to improve food safety. This study presents an analysis of Whole Genome source tracking implementation on potential food contamination and related illnesses through theoretical, empirical, and cost benefit analyses. We conduct empirical tests using data from FDA regulated food commodity outbreaks garnering FDA response from 1999 through 2019 and examine the effect of the National Center for Biotechnology Information (NCBI) Pathogen detection program of source tracking WGS isolates collected in the U.S. on outbreak illnesses for three pilot pathogens (E. coli, Listeria, and Salmonella). Empirical results are consistent with the theoretical model and suggest that each additional 1,000 WGS isolates added to the public NCBI database is associated with a reduction of approximately 6 illnesses per WGS pathogen, per year. Empirical results are connected to existing literature for a Monte Carlo analysis to estimate benefits and costs. By 2019, annual health benefits are estimated at nearly $500 million, compared to an approximately $22 million investment by public health agencies. Even under conservative assumptions, the program likely broke even in its second year of implementation and could produce increasing public health benefits as the GenomeTrakr network matures. Public Library of Science 2021-10-06 /pmc/articles/PMC8494326/ /pubmed/34614029 http://dx.doi.org/10.1371/journal.pone.0258262 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Brown, Brad Allard, Marc Bazaco, Michael C. Blankenship, Joseph Minor, Travis An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S. |
title | An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S. |
title_full | An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S. |
title_fullStr | An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S. |
title_full_unstemmed | An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S. |
title_short | An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S. |
title_sort | economic evaluation of the whole genome sequencing source tracking program in the u.s. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494326/ https://www.ncbi.nlm.nih.gov/pubmed/34614029 http://dx.doi.org/10.1371/journal.pone.0258262 |
work_keys_str_mv | AT brownbrad aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT allardmarc aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT bazacomichaelc aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT blankenshipjoseph aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT minortravis aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT brownbrad economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT allardmarc economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT bazacomichaelc economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT blankenshipjoseph economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus AT minortravis economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus |